ClinicalTrials.gg
RecruitingNCT06925217CLICKUpdated Feb 12, 2026

Closed-Loop Impact on Chronic Kidney Disease in Type 2 Diabetes

An interventional study of CamAPS HX and Standard insulin therapy with CGM in Type 2 Diabetes and Chronic Kidney Disease Stage 3, sponsored by Heba Al-Alwan. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Heba Al-Alwan · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland — 13 open to participants now, 18 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Switzerland.

Planned enrollment
64th of 91
76 · median 330
Started
2025
with 4 others
No phase
22 of 112
6 open now
Primary completion
2027-05
later than 8 of 17 live
Registered
105th of 112
by date

Among the 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland, this one is the 64th largest by planned enrollment of the 91 interventional ones that give a count, is one of 5 that started in 2025, is one of 22 with no phase, reaches primary completion later than 8 of the 17 other live ones, and was the 105th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

13 of the 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Diabetes Mellitus, Type 2 with a site in Switzerland, or all of them as a file.
02

Study summary

The main objective of this study is to evaluate the effect of fully automated closed-loop glucose control on renal tissue oxygenation among people with type 2 diabetes and chronic kidney disease.

This is a single-center, open-label parallel design study that will compare 26 weeks of fully-automated closed-loop glucose control with standard insulin therapy and continuous glucose monitoring, following a run-in period. A total of up to 76 adults with type 2 diabetes and chronic kidney disease will be recruited through outpatient diabetes and nephrology clinics.

The primary outcome is renal tissue oxygenation measured using blood oxygenation level-dependent magnetic resonance imaging at 26 weeks. Other key outcomes include glycated hemoglobin at 26 weeks and time spent with glucose levels within and above the target glucose range (3.9-10.0mmol/L). Other glycemic and renal outcomes (including renal function) will also be assessed, as well as patient-reported outcome measures using validated questionnaires. Safety evaluations include severe hypoglycemic episodes and other adverse and serious adverse events.

Read the detailed description

Recruitment:

The investigators aim to recruit 76 participants through the Service of Endocrinology, Diabetes, and Metabolism and through the Nephrology and Hypertension Service at the University Hospital of Lausanne (CHUV), as well as other outpatient diabetes clinics in the canton of Vaud if needed.

Screening visit:

Potential participants will have the opportunity to ask questions and will give written informed consent if interested in participating in the study. A screening blood test, a urine analysis, and urine pregnancy test will be done at this visit.

Baseline visit:

The baseline assessment will consist of a medical history, height and weight measurement, waist-hip ratio measurement and blood pressure measurement. Participants will also answer questionnaires to assess patient-reported outcome measures and undergo a renal MRI. A masked glucose sensor will be worn for 14 days.

Visit 3:

Randomisation will occur in a 1:1 ratio using REDCap to the use of fully closed-loop therapy or standard insulin therapy with continuous glucose monitoring (CGM) for 26 weeks once the participants complete the masked CGM period. Participants will attend the research center and receive training on study devices (closed-loop system or CGM) and study devices will be initiated.

Visit 4:

Participants will attend the research center around two days after initiation of the study arm to discuss potential issues related to use of study devices. This visit can also be conducted by phone.

Telephone contacts:

Participants in both arms will be contacted by telephone 1 week after initiation of the study arm, as well as at one, two, four, and five months after initiation of study arm to discuss any issues with devices, adverse events, or changes to medications.

Visit 5 (3 month visit):

Participants will attend the research center and fill-out questionnaires and a blood test and urine analysis will be performed.

Visit 6 (6 month visit):

Participants will attend the research center and fill-out questionnaires and a blood test and urine analysis will be performed. A renal MRI will be repeated at this visit. Study devices will be returned, and participants will resume their usual diabetes care.

Patient-reported outcomes:

Patient-reported outcome measures will be assessed using five validated questionnaires: Diabetes Distress Scale, Hypoglycemia Attitudes and Behavior Scale, Audit of Diabetes-Dependent Quality of Life, Diabetes Treatment Satisfaction Questionnaire - status version, Diabetes Treatment Satisfaction Questionnaire - change version

Safety outcomes:

Safety outcomes will include the number of severe hypoglycemia episodes, as well as the nature and severity of other adverse events including serious adverse events.

03

Conditions studied

  • Type 2 Diabetes
  • Chronic Kidney Disease Stage 3

Keywords

  • closed-loop
  • type 2 diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • signed by the subject
  • Age 18 years and older
  • Type 2 diabetes diagnosed for at least 12 months
  • Treatment with insulin therapy for at least 6 months
  • CKD defined either as an 30-59 ml/min/1.73m² or presence of albuminuria > 3 mg/mmol (stage A2 or A3 according to KDIGO) with an eGFR > 30 ml/min/1.73m². CKD must be present for at least 6 months.
  • \< 12% based on a venous blood sample from the screening visit
  • Receiving treatment with an SGLT2 inhibitor and/or GLP-1 receptor agonist for at least 3 months, have been offered these therapies previously, or /intolerance to receiving these therapies
  • Willing to wear study devices and follow study instructions
  • Capable of giving an informed consent

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • Current use of insulin pump
  • Current use of any closed-loop system
  • Alternative cause of CKD according to medical records such as polycystic kidney disease, glomerulonephritis, congenital urogenital tract diseases, etc.
  • Known or suspected allergy against insulin
  • Pregnancy, planned pregnancy, or breast feeding
  • Severe visual impairment
  • Severe hearing impairment
  • Two or more episodes of severe hypoglycemia in the last 6 months
  • Medically documented allergy towards the adhesive (glue) of plasters
  • Serious skin diseases located at places of the body, which potentially are possible to be used for localisation of the glucose sensor
  • Any physical/psychological disease or medication(s) likely to interfere with the conduct of the study and interpretation of the study results, as judged by study clinician
  • Recent (less than three months) history of myocardial infarction, percutaneous coronary intervention, stroke, or hospitalization for heart failure with reduced
  • History of renal transplantation requiring ongoing therapy
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow the procedures of the investigation, e.g. due to language problems
  • Incapacity to give
  • to undergo MR-imaging according to a standard checklist such as the presence of a pacemaker or other implanted metallic device or severe claustrophobia.
  • Subject refuses to be informed of incidental findings related to their health discovered during imaging or other study-related exams
  • Participation in another investigation with an drug or another MD within the 30 days preceding and during the present investigation
  • Previous enrolment into the current investigation
  • Enrolment of the PI, his/her family members, employees and other dependent persons
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    Fully closed-loop insulin delivery (CamAPS HX)

    The CamAPS HX closed-loop system will consist of : * mylife Ypsopump insulin pump (Ypsomed, Switzerland) * FreeStyle Libre 3 CGM (Abbott, USA) * Cambridge model predictive control algorithm on a smartphone (CamAPS, UK) * Cloud upload system to review CGM/insulin data

    Device: CamAPS HX

  • Active comparator
    Standard insulin therapy with CGM

    Participants in the control arm will continue their standard insulin therapy. They will also receive a Freestyle Libre 3 glucose sensor (Abbott, USA).

    Device: Standard insulin therapy with CGM

Interventions

  • DeviceCamAPS HX

    The CamAPS HX fully closed-loop system consists of an insulin pump, a continuous glucose monitoring (CGM) sensor, as well as the CamAPS HX app, which resides on a smartphone and communicates wirelessly with the insulin pump.

  • DeviceStandard insulin therapy with CGM

    Participants will continue their standard insulin therapy with a Freestyle Libre 3 CGM

06

What researchers measure

Primary outcomes

  1. Cortical renal tissue oxygenation (R2*)

    Measured using BOLD-MRI

    Time frame: at 26 weeks

Secondary outcomes

  1. Proportion of time spent in the target glucose range (3.9 to 10.0mmol/l)

    Sensor glucose metric measured as a percentage

    Time frame: over 26 weeks

  2. Glycated hemoglobin

    Time frame: at 26 weeks

  3. Proportion of time spent above target glucose (>10.0mmol/l)

    Sensor glucose metric measured as a percentage

    Time frame: over 26 weeks

  4. Mean sensor glucose

    Sensor glucose metric measured in mmol/l

    Time frame: over 26 weeks

  5. Non-inferiority for time spent below target glucose (<3.9mmol/L)

    Sensor glucose metric measured as a percentage

    Time frame: over 26 weeks

  6. Standard deviation of sensor glucose

    Sensor glucose metric measured in mmol/L

    Time frame: over 26 weeks

  7. Coefficient of variation of sensor glucose

    Sensor glucose metric measured as a percentage

    Time frame: over 26 weeks

  8. Proportion of time spent below target glucose (<3.5mmol/L)

    Sensor glucose metric measured as a percentage

    Time frame: over 26 weeks

  9. Proportion of time spent below target glucose (<3.0mmol/L)

    Sensor glucose metric measured as a percentage

    Time frame: over 26 weeks

  10. Proportion of time spent above target glucose (>13.9mmol/l)

    Sensor glucose metric measured as a percentage

    Time frame: over 26 weeks

  11. Proportion of time spent above target glucose (>16.7mmol/l)

    Sensor glucose metric measured as a percentage

    Time frame: over 26 weeks

  12. Proportion of time spent above target glucose (>20.0mmol/l)

    Sensor glucose metric measured as a percentage

    Time frame: over 26 weeks

  13. Per-kidney renal perfusion (ml/min)

    MRI-assessed outcome

    Time frame: at 26 weeks

  14. Kidney inflammation (T1, msec)

    MRI-assessed outcome

    Time frame: at 26 weeks

  15. Medullary renal tissue oxygenation (R2*)

    measured using BOLD-MRI

    Time frame: at 26 weeks

  16. R2* slope

    measured using BOLD-MRI

    Time frame: at 26 weeks

  17. Serum creatinine (umol/l)

    Time frame: at 26 weeks

  18. Serum urea (umol/l)

    Time frame: at 26 weeks

  19. Urine albumin/creatinine ratio (ACR)

    Time frame: at 26 weeks

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data can be requested by other researchers 6 months following publication (data available upon reasonable request). To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for May 2027, 23 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 23 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2025
First posted
Apr 13, 2025
StartActual
Jun 16, 2025
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06925217
Lead sponsor
Heba Al-Alwan
Collaborators
Swiss National Science Foundation, Institute of Primary Health Care (BIHAM), Switzerland
Responsible party
Heba Al-Alwan (Medical doctor, Centre Hospitalier Universitaire Vaudois) — Sponsor-investigator
First posted
Apr 13, 2025
Start date
Jun 16, 2025
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Feb 12, 2026

Study contacts

Heba Al-Alwan, MD, PhD
Contact
heba.al-alwan@chuv.ch
+4179 556 27 98

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion